Winner
Tillotts IDEAL Education
Summary of work
The Tillotts Infectious Diseases Education And Learning (IDEAL) programme, launched in July 2023 by Tillotts Pharma UK (TPUK), is making a significant impact in upskilling UK healthcare professionals (HCPs) in the diagnosis, management and treatment of patients with/suspected Clostridioides difficile infections (CDI) by providing comprehensive online training modules.
CDI is the leading cause of hospital-acquired infectious diarrhoea in adults.(1,2)
Tillotts acquired fidaxomicin, a narrow-spectrum antibiotic indicated for CDI, in 2021, and we have been committed to supporting HCPs in combatting this life-threatening disease ever since.
The provision of value for the NHS is at the heart of the IDEAL programme. The educational modules, created by the TPUK medical team, are developed in close collaboration with CDI experts, ensuring the content is up-to-date and relevant to participants. Subject matter is broken up into bite-sized modules and delivered through a dedicated online platform, to meet the needs of time-poor HCPs. The platform is promoted through a multichannel strategy utilising a range of media formats.
Within the first year of launch, 362 HCPs completed 1,099 e-learning modules across the UK.
This consistent engagement, combined with overwhelmingly positive feedback, is a testament to the growing interest in and value of IDEAL.
Judges’ comments
The judges felt that this was an excellent entry and that what set it apart were the behavioural metrics and the impact. It had a clear, agile response to engagement issues and was clean and simple, with an effective go-to-market approach. It had good smart objectives and impact metrics, with clear insights on what they were trying to achieve. The judges particularly liked the approach, the internal cross functional engagement and that insights were gathered from the advisory boards.
